Suppr超能文献

GPER1/SPOP 轴介导 ERα 的泛素化依赖性降解,从而抑制雌激素诱导的乳腺癌生长。

The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.

机构信息

Department of Physiology, Zhongshan School of Medicine, Sun Yat-Sen University,. Zhongshan Road 2, Guangzhou 510080, PR China.

Department of Pathology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Dongfeng East Road, Guangzhou 510080, PR China.

出版信息

Cancer Lett. 2021 Feb 1;498:54-69. doi: 10.1016/j.canlet.2020.10.019. Epub 2020 Oct 15.

Abstract

G protein-coupled oestrogen receptor 1 (GPER1), predicted to be a novel oestrogen receptor, has been linked to the development and progression of breast cancer. However, the molecular mechanisms underlying its functions remain elusive. Here, we show that the protein levels of GPER1 are negatively associated with those of ERα and that higher expression of GPER1 correlated with a better clinical outcome in oestrogen receptor-positive (ER+) breast cancer patients. Activation of GPER1 decreases ERα protein levels, which subsequently suppresses ERα-mediated transcription and target gene expression but does not affect its mRNA expression in ER + breast cancer cells. A mechanistic study revealed that GPER1 mediates ubiquitin (Ub)-proteasome-dependent degradation of ERα via upregulation of the Cullin3-based E3 ubiquitin ligase adaptor protein speckle-type POZ protein (SPOP), and depletion of SPOP abrogates GPER1-induced ERα ubiquitination and degradation. Functionally, GPER1 activation inhibits 17β-oestradiol (E2)-induced ER + breast cancer cell proliferation, migration, and invasion in vitro and tumour growth in vivo. Our findings reveal a novel mechanism by which GPER1 negatively modulates the ERα signalling pathway via promoting its ubiquitin-proteasome-dependent degradation, which may contribute to its inhibition of breast cancer progression.

摘要

G 蛋白偶联雌激素受体 1(GPER1)被预测为一种新型雌激素受体,与乳腺癌的发生和发展有关。然而,其功能的分子机制仍不清楚。在这里,我们表明 GPER1 的蛋白水平与 ERα 的蛋白水平呈负相关,并且在雌激素受体阳性(ER+)乳腺癌患者中,GPER1 的高表达与更好的临床结局相关。GPER1 的激活降低了 ERα 蛋白水平,进而抑制了 ERα 介导的转录和靶基因表达,但不影响其在 ER+乳腺癌细胞中的 mRNA 表达。一项机制研究表明,GPER1 通过上调 Cullin3 基 E3 泛素连接酶衔接蛋白 speckle-type POZ 蛋白(SPOP)介导 ERα 的泛素(Ub)-蛋白酶体依赖性降解,并且 SPOP 的耗竭会消除 GPER1 诱导的 ERα 泛素化和降解。功能上,GPER1 的激活抑制了 17β-雌二醇(E2)诱导的 ER+乳腺癌细胞在体外的增殖、迁移和侵袭以及体内的肿瘤生长。我们的研究结果揭示了一种新的机制,即 GPER1 通过促进 ERα 的泛素-蛋白酶体依赖性降解来负调控 ERα 信号通路,这可能有助于其抑制乳腺癌的进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验